SEC Foi	rm 4 FORM	4 L	INITE	D STAT	ES	SEC					XCHAN	IGE	со	MMI	SSIO	N			
to Section 16. Form 4 or Form 5 obligations may continue. See				Washington, D.C. 20549 <b>IT OF CHANGES IN BENEFICIAL OWNI</b> pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										SHIP	OMB	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		3235-0287 en	
1. Name and Address of Reporting Person* <u>HO WILLIAM</u> (Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE				2. Issuer Name and Ticker or Trading Symbol <u>RAPT Therapeutics, Inc.</u> [ RAPT ]     3. Date of Earliest Transaction (Month/Day/Year)     02/28/2022								(Che	Relationship of Reporting Person(s) to Issuer teck all applicable) Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer						
(Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Bene	ficiall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execution Date,			Transaction Di			4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)					Forr (D) c	n: Direct	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or F	Price	Transa	ed ction(s) 3 and 4)			(Instr. 4)	
Common Stock 02/28/2					022			S <sup>(1)</sup>		3,000	D	) 5	\$18.79	3.79 55,69			D		
		Ta	ble II -								osed of, convertib				Ownee	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) if any of (Month/Day/Year) itive		ion Date,	4. Transaction Code (Instr. 8) Code V		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and 5	rities iired r osed ) 7. 3, 4			te	() Securit Underh Derivat Securit 3 and 4		De Se (Ir	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

**Remarks:** 

## <u>/s/ Rodney Young, Attorney-</u> in-Fact for William Ho

02/28/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.